J&J to buy Momenta Pharmaceuticals for $6.5B August 20, 2020 Auto Bot autoimmune disease, BioPharma, biopharma nl, Cambridge, Johnson & Johnson, Massachusetts, New Jersey 0 The drugmaker emphasized the full global rights it would acquire to Momenta’s lead asset, nipocalimab, which it is developing for several autoantibody-driven diseases and that in certain indications could have peak sales of more than $1 billion.